Results 21 to 30 of about 12,405 (251)

Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc

AIDS (London), 2021
Supplemental Digital Content is available in the text Objective: To evaluate the effect on anthropometric, metabolic and adipose tissue parameters of switching ART-controlled persons living with HIV (PLWH) from a protease inhibitor regimen to raltegravir/
J. Bastard, V. Pelloux, R. Alili, S. Fellahi, J. Aron‐Wisnewsky, Emilie Capel, B. Fève, L. Assoumou, Edi Prifti, C. Katlama, K. Clément, J. Capeau   +11 more
semanticscholar   +1 more source

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir [PDF]

Antimicrobial Agents and Chemotherapy, 2011
ABSTRACT The identification of transporters of the HIV integrase inhibitor raltegravir could be a factor in an understanding of the pharmacokinetic-pharmacodynamic relationship and reported drug interactions of raltegravir.
Andrew Owen, Marco Siccardi, Neill J. Liptrott, Saye Khoo, Darren Smith, Wai San Kwan, David Back, Darren M. Moss   +7 more
openaire   +2 more sources

Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study

Acta Médica Portuguesa, 2022
Introduction: Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy.
Rosário Serrão, Kamal Mansinho, Fernando Maltez, Nuno Marques, Alexandre Carvalho, Rosário Pazos, Alexandra Zagalo, Josefina Mendez, Isabel Neves, Joaquim Oliveira, Patrícia Pacheco, Ricardo Correia de Abreu, Ana Cláudia Miranda, Paula Camacho, Laura Paixão, Joana Almeida   +15 more
doaj   +1 more source

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. [PDF]

PLoS ONE, 2014
The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed.
Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings   +30 more
doaj   +1 more source

Raltegravir Pharmacokinetics During Pregnancy [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
We evaluated the pharmacokinetics (PK) of raltegravir in HIV-infected women during pregnancy and postpartum.International Maternal Pediatric Adolescent AIDS Clinical Trials 1026s is an ongoing prospective study of antiretroviral PK during pregnancy (NCT00042289).
Watts, D Heather, Stek, Alice, Best, Brookie M, Wang, Jiajia, Capparelli, Edmund V, Cressey, Tim R, Aweeka, Francesca, Lizak, Patty, Kreitchmann, Regis, Burchett, Sandra K, Shapiro, David E, Hawkins, Elizabeth, Smith, Elizabeth, Mirochnick, Mark   +13 more
openaire   +6 more sources

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

The Pediatric Infectious Disease Journal, 2021
We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and
Tom G. Jacobs, K. V. van Aerde, A. Colbers, D. Burger   +3 more
semanticscholar   +1 more source

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. [PDF]

PLoS ONE, 2016
BACKGROUND:Irinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods.
Lawrence Soon-U Lee, Kok-Yong Seng, Ling-Zhi Wang, Wei-Peng Yong, Kim-Hor Hee, Thomas I Soh, Andrea Wong, Pei F Cheong, Richie Soong, Nur S Sapari, Ross Soo, Lu Fan, Soo-Chin Lee, Boon C Goh   +13 more
doaj   +1 more source

HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor-based second-line failure in a dedicated resistance clinic in western Kenya: a retrospective cohort study. [PDF]

J Int AIDS Soc
Abstract Introduction Data on drug resistance, viral outcomes and guidelines compliance following protease inhibitor (PI)‐based second‐line failure in low‐ and middle‐income countries are limited, particularly in the era of dolutegravir‐containing antiretroviral therapy (ART). Methods We conducted a retrospective cohort study of people living with HIV (
Humphrey JM, Ali SM, DeLong A, Novitsky V, Sang E, Jawed B, Kemboi E, Ngetich C, Goodrich S, Gardner A, Hogan JW, Kantor R.   +11 more
europepmc   +2 more sources

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

Cells, 2022
Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study
Gaurav Kumar, Jacqueline Cottalorda-Dufayard, Rodolphe Garraffo, Francine De Salvador-Guillouët, Eric Cua, Pierre-Marie Roger   +5 more
doaj   +1 more source

HIV resistance to raltegravir [PDF]

European Journal of Medical Research, 2009
Similar to all antiretroviral drugs, failure of raltegravir-based treatment regimens to fully supress HIV replication almost invariably results in emergence of HIV resistance to this new drug. HIV resistance to raltegravir is the consequence of mutations located close to the integrase active site, which can be divided into three main evolutionary ...
openaire   +5 more sources